Biogen has picked former Sanofi CEO
The company said Thursday that the 62-year-old Viehbacher will become president and CEO on Monday, replacing
Biogen said in May that Vounatsos would leave as soon as the company found a successor. The announcement came less than a year after Biogen introduced the first new Alzheimer’s drug in nearly two decades at a price — about
Biogen later slashed that price, but the drug's launch has been hampered by tight coverage restrictions imposed by the federal government’s Medicare program and a hesitancy from doctors to prescribe it. By last spring, Biogen had decided to eliminate most of its spending on a drug that analysts once thought would generate billions of dollars in annual revenue.
Aduhelm brought in
Viehbacher served six years as CEO of Sanofi before the French drugmaker sacked him in 2014.
The company’s share price more than doubled during Viehbacher’s tenure, which was marked by a
Before Sanofi, Viehbacher served as an executive with British drugmaker
Shares of
Follow
Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source